{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:35:32Z","timestamp":1761964532852},"reference-count":31,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Exp Hematopathol","JCEH"],"published-print":{"date-parts":[[2013]]},"DOI":"10.3960\/jslrt.53.227","type":"journal-article","created":{"date-parts":[[2013,12,24]],"date-time":"2013-12-24T22:47:47Z","timestamp":1387925267000},"page":"227-233","source":"Crossref","is-referenced-by-count":4,"title":["Monocytic Crisis of Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitor"],"prefix":"10.3960","volume":"53","author":[{"given":"Hiroko","family":"Tsunemine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Arima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiminari","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiko","family":"Sakane-Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Akasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiichi","family":"Kodaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","unstructured":"1 Nowell PC, Hungerford DA: Chromosome studies in human leukemia. II. Chronic granulocytic leukemia. J Natl Cancer Inst 27:1013-1035, 1961"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Spiers AS: The clinical features of chronic granulocytic leukaemia. Clin Haematol 6:77-95, 1977","DOI":"10.1016\/S0308-2261(21)00550-6"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Kurzrock R, Gutterman JU, Talpaz M: The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 319:990-998, 1988","DOI":"10.1056\/NEJM198810133191506"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, <I>et al<\/I>.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004, 2003","DOI":"10.1056\/NEJMoa022457"},{"key":"5","unstructured":"5 Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, Druker BJ, <I>et al<\/I>.: Survival advantage from imatinib compared with the combination interferon-&alpha; plus cytarabine in chronic-phase chronic myelogenous leukemia: Historical comparison between two phase 3 trials. Blood 108:1478-1484, 2006"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Marin D, Milojkovic D, Olavarria E, Khorashad JS, de Lavallade H, <I>et al<\/I>.: European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 112:4437-4444, 2008","DOI":"10.1182\/blood-2008-06-162388"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Leder LD, Mischke W, Garbrecht M, Stolzenbach G: Terminal Ph 1-positive monocytic crisis in chronic myeloid leukemia providing evidence for the promyelocytic origin of monocytes. Klin Wochenschr 57:237-242, 1979","DOI":"10.1007\/BF01477492"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Ondreyco SM, Kjeldsberg CR, Fineman RM, Vaninetti S, Kushner JP: Monoblastic transformation in chronic myelogenous leukemia: Presentation with massive hepatic involvement. Cancer 48:957-963, 1981","DOI":"10.1002\/1097-0142(19810815)48:4<957::AID-CNCR2820480418>3.0.CO;2-6"},{"key":"9","unstructured":"9 Fujii H, Seki S, Misawa S, Sonoda Y, Kita K: Ph-1 positive chronic myelogenous leukemia with simultaneous erythroblastic and monoblastic transformation. Nihon Ketsueki Gakkai Zasshi 46:1056-1069, 1983 (<I>in Japanese<\/I>)"},{"key":"10","unstructured":"10 Cuneo A, Barbieri D, Ferraresi P, Castoldi GL: A case of chronic myelogenous leukemia with 11q- in blast crisis with monoblastic differentiation. Nouv Rev Fr Hematol 27:389-391, 1985"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Yao E, Sadamori N, Tomonaga Y, Matsunaga M, Tagawa M, <I>et al<\/I>.: A new complex translocation in chronic myelogenous leukemia with monoblastic crisis. Cancer Genet Cytogenet 19:357-359, 1986","DOI":"10.1016\/0165-4608(86)90068-3"},{"key":"12","unstructured":"12 Buonanno G, Pandolfi F, Valente A, Napolitano M, Cafaro A, <I>et al<\/I>.: Monocytic blast cell crisis and IgG-&lambda; monoclonal gammopathy in a ph<SUP>1+<\/SUP> chronic myelogenous leukemia. Report of a case. Haematologica 71:489-492, 1986"},{"key":"13","unstructured":"13 Sugita K, Nakazawa S, Mori T, Nishino K, Abe T, <I>et al<\/I>.: Monocytic crisis in chronic myeloid leukemia: A case report. Rinsho Ketsueki 30:376-381, 1989 (<I>in Japanese<\/I>)"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Yamauchi K, Nagao T, Yamazaki H: Leukemic pneumonitis in monocytic crisis of chronic myelogenous leukemia. Am J Hematol 37:286-287, 1991","DOI":"10.1002\/ajh.2830370418"},{"key":"15","unstructured":"15 Harigae H, Nomura J, Furuyama K, Shishido T, Okuda M, <I>et al<\/I>.: A case of monoblastic crisis of CML beginning with extramedullary tumor formation in a rib. Rinsho Ketsueki 33:806-810, 1992 (<I>in japanese<\/I>)"},{"key":"16","unstructured":"16 Wakimoto N, Yokoyama A, Mukai Y, Kuwada N, Yamashita T, <I>et al<\/I>.: Elevated expression of differentiation inhibitory factor nm 23 mRNA in monoblastic crisis of a patient with chronic myelogenous leukemia. Int J Hematol 67:313-318, 1998"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Abdelmoula NB, Van den Akker J, Portno&iuml; MF, Perot C, Taillemite JL: A variant translacation (9;22;22) with local extramedullary monoblastic transformation in CML. Cancer Genet Cytogenet 123:69-70, 2000","DOI":"10.1016\/S0165-4608(00)00302-2"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Marin D, Bazeos A, Mahon FX, Eloasson L, Milojkovic D, <I>et al<\/I>.: Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic resonses on imatinib. J Clin Oncol 28:2381-2388, 2010","DOI":"10.1200\/JCO.2009.26.3087"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, <I>et al<\/I>.: Poor adherence is the main reason for loss of CCyR andimatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 117:3733-3736, 2011","DOI":"10.1182\/blood-2010-10-309807"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Melo JV, Deininger MW: Biology of chronic myelogenous leukemia-signaling pathways of initiation and transformation. Hematol Oncol Clin North Am 18:545-568, 2004","DOI":"10.1016\/j.hoc.2004.03.008"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Johansson B, Fioretos T, Mitelman F: Cytogenetic and molecular genetic evolution of chronic myeloid keukemia. Acta Haematol 107:76-94, 2002","DOI":"10.1159\/000046636"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Calabretta B, Perrotti D: The biology of CML blast crisis. Blood 103:4010-4022, 2004","DOI":"10.1182\/blood-2003-12-4111"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Karbasian Esfahani M, Morris EL, Dutcher JP, Wiernik PH: Blastic phase of chronic myelogenous leukemia. Curr Treat Options Oncol 7:189-199, 2006","DOI":"10.1007\/s11864-006-0012-y"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 O'Hare T, Eide CA, Deininger MW: Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110:2242-2249, 2007","DOI":"10.1182\/blood-2007-03-066936"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Bixby D, Talpaz M: Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology Am Soc Hematol Educ Program 461-476, 2009","DOI":"10.1182\/asheducation-2009.1.461"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Giles FJ, Kantarjian HM, le Coutre PD, Baccarani M, Mahon FX, <I>et al<\/I>.: Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia 26:959-962, 2012","DOI":"10.1038\/leu.2011.355"},{"key":"27","unstructured":"27 le Coutre PD, Giles FJ, Hochhaus A, Apperley JF, Ossenkoppele GJ, <I>et al<\/I>.: Nilotinib in patients with Ph<SUP>+<\/SUP> chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia 26:1189-1194, 2012"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Noguchi M, Oshimi K: Extensive bone marrow necrosis and symptomatic hypercalcemia in B cell blastic transformation of chronic myeloid leukemia: Report of a case and review of the literature. Acta Haematol 118:111-116, 2007","DOI":"10.1159\/000106100"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Burton C, Azzi A, Kerridge I: Adverse events after imatinib mesylate therapy. N Engl J Med 346:712-713, 2002","DOI":"10.1056\/NEJM200202283460919"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Campiotti L, Codari R, Appio L, Ultori C, Solbiati F, <I>et al<\/I>.: Bone marrow necrosis related to imatinib mesylate therapy for cml bilineal blast crisis. Leuk Res 31:1768-1770, 2007","DOI":"10.1016\/j.leukres.2007.02.012"},{"key":"31","unstructured":"31 Tamura T, Tasaka T, Fujimoto M, Matsuhashi Y, Fukumot T, <I>et al<\/I>.: Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy. Haematologica 89:ECR32, 2004"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,3,20]],"date-time":"2022-03-20T15:56:31Z","timestamp":1647791791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/53\/3\/53_227\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.53.227","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}